Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial

What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?

(2009) Stéphane Oudard et al.   BJU INTERNATIONAL

Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial

(2008) Orazio Caffo et al.   BJU INTERNATIONAL

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

(2008) D. R. Berthold et al.   CLINICAL CANCER RESEARCH

Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib

(2008) Edwin Herrmann et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Validation of Patient's Self-Reported Social Functioning As an Independent Prognostic Factor for Survival in Metastatic Colorectal Cancer Patients: Results of an International Study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer

(2008) Fabio Efficace et al.   JOURNAL OF CLINICAL ONCOLOGY

Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy

(2008) Se Hoon Park et al.   QUALITY OF LIFE RESEARCH

Pretreatment Quality of Life Predicts for Locoregional Control in Head and Neck Cancer Patients: A Radiation Therapy Oncology Group Analysis

(2007) Farzan Siddiqui et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS